| Literature DB >> 24829927 |
H G Alvarenga1, L Marti1.
Abstract
Fibroblastic reticular cells (FRCs) are stromal cells found in secondary lymphoid organ. Despite its structural function in the lymph nodes being well established, recent studies indicate that the FRCs also play a key role in immunological processes, associated with cell transit, immune response, and cells activation quality, and contribute to peripheral tolerance. To this end, we focus this review on lymph nodes FRC characterization and discuss functional aspects such as production of cytokines and chemokines and their involvement in the immune response, seeking to establish whether certain subsets have a more functional specialization.Entities:
Mesh:
Year: 2014 PMID: 24829927 PMCID: PMC4009236 DOI: 10.1155/2014/402038
Source DB: PubMed Journal: J Immunol Res ISSN: 2314-7156 Impact factor: 4.818
Figure 1Schematic representation of FRCs. They are spatially arranged so as to delimit a conduit channel that drives soluble molecules. Other structures evidenced are the FRC intracellular cytoplasmic channels, through which antigens are transported from the lymph to the nearby-lying antigen-presenting cells.
FRC characterization markers. FRC was classified by species, surface or intracellular makers, inducible markers and ones that exclude other cells presence, and chemokines and cytokines secretion, listed in time order of publishing.
| Publication year—author | Markers | Chemokines | Cytokines | ||||
|---|---|---|---|---|---|---|---|
| Surface | Intracellular | Inducible | Excluding | Regular | Inducible | ||
| 2004—Katakai et al. (a) [ | CD44, gp38, CD106 | ER-TR7 | CD54 | CD11b/CD18, CD16,CD31, CD32, CD35, MHCII, LYVE1 | CCL2, CXCL12, CX3CL1 | CCL4, CCL5, CCL20, CXCL10 | IL6, IL7, IL15 |
| 2004—Katakai et al. (b) [ | — | ER-TR7 | — | — | — | — | — |
| 2005—Sixt et al. [ | gp38, | ER-TR7 | — | — | — | — | — |
| 2006—Bajénoff et al. [ | Desmin, CD106, CD54 | ER-TR7 | — | — | CCL19, CCL21, CXCL12 (SDF-1) | — | — |
| 2006—Hara et al. [ | gp38, CD106 | ER-TR7 | — | — | — | CXCL16 | IL7, IL15 |
| 2007—Amé-Thomas et al. [ | CD73, CD90, CD105 | — | CD54 | CD21, CD23, CD35, CD45 | CCL5, CXCL9, CXCL10, CXCL12 | CCL19 | — |
| 2007—Link et al. [ | gp38, | ER-TR7 | — | CD21, CD31, CD35 CD45, LYVE-1 | CCL19, CCL21 | — | IL7 |
| 2009—Roozendaal et al. [ | gp38 | ER-TR7 | — | — | — | — | — |
| 2009—Mueller and Germain [ | gp38, PDL1 | VEGF, ER-TR7 | — | CD45, CD31, CD21, CD35, C4, CD16, CD23, CD32, CD157, Mfge8 | CCL19, CCL21 | — | IL7 |
|
2009—Steel et al. [ | gp38, p75NGFR, TTG, CD54, CD106, CD157, LT | ER-TR7 | — | — | CCL19, CCL21, CXCL16, CCL2/MCP1 | — | IL7, IL6 |
| 2010—Turley et al. [ | gp38, PDL1 | DEAF1 | CD31 | CCL19, CCL21 | — | IL7 | |
| 2011—Khan et al. [ | gp38, PDL1 | — | iNOS | CD45, CD31 | CCL19, CCL21 | — | IL7 |
| 2011—Luther et al. [ | gp38, CD54, CD106, CD157, PDGFR | VEGF | — | CD21, CD31, CD35, CD45, C4, Mfge8 | CCL19, CCL21 | CCL2, CCL4, CCL5, CXCL12, CXCL16, CX3CL1 | IL7, IL6 |
| 2011—Link et al. [ | gp38, CD54, CD106, CD157, PDGFR | ERTR7 | — | CD31, CD35, CD45 | CCL19, CCL21 | — | IL7 |
| 2011—Onder et al. [ | gp38 | — | — | CD31, CD45 | CCL19, CCL21 | — | IL7 |
| 2011—Fletcher et al. (a) [ | gp38, PDGF | VEGF | — | CD45, CD31 | CCL19, CCL21 CXCL9, CXCL10 | — | IL7 |
| 2011—Fletcher et al. (b) [ | gp38, PDGF | VEGF | — | CD45, CD31 | CCL19, CCL21, CXCL12 (SDF1) | — | IL7 |
| 2011—Frontera et al. [ | CD54, CD106, PDGF | JAMC | — | CD45, CD31, LYVE1 | CCL21 | — | — |
| 2011—Siegert et al. [ | gp38 | iNOS | — | CD45, CD35, CD31, EpCAM | CCL19, CCL21 | — | IL7 |
|
2011—Lukacs-Kornek [ | gp38, PDL1, INFGR1, TNFR1, TNFR2 | NOS2, IDO | — | CD45, CD31 | CCL19, CCL21 | — | — |
| 2012—Zeng et al. [ | Desmin | — | — | CD35, CD21 | — | — | — |
| 2012—Siegert and Luther [ | gp38, PDL1 | COX2, Aire, DEAF1, NO | iNOS, MHCII, IDO, CD80 | CD21, CD35, CD31 | CCL19, CCL21 | — | IL7 |
|
2012—Graw and Regoes [ | — | — | — | — | CCL19, CCL21 | — | — |
| 2012—Onder et al. [ | gp38 | — | — | CD31, CD45 | CCL19, CCL21 | — | IL7 |
| 2012—Hess et al. [ | gp38, CD106, MadCAM1 | RankL | — | CD31, CD45 | — | — | IL7 |
| 2012—Malhotra et al. [ | gp38, CD140a | VEGFA and C, ANGPTL2 and 4, HGF, GREM1, SERPINF1 cadherin-11, IFITM-1, Flt3L | — | CD31, CD45 | CXCL14, CCL19, CCL21, CXCL13 CXCL12, CCL2, CCL7 | IL34 | |
| 2012—Acton et al. [ | gp38 | — | — | CD31 | CCL19, CCL21 | — | — |
| 2013—Chai et al. [ | gp38, | ER-TR7, NO | — | CD31, CD45 | CCL19, CCL21 | — | IL-7 |
| 2014—Yang et al. [ | gp38, PDGFR | VEGF, iNOS, VEGF, MyD88 | — | CD31, CD45, LYVE-1 | CCL19, CCL21 | — | IL-7 |
Murine lymph node (MLN); human tonsils (HT); nonhuman primate lymph node (NHPLN); murine and human lymph node (MHLN).
Figure 2Schematic representation of lymph node and cells classification [4–6]: (A) FRC in the T cell zone (TRC)− gp38+ CD157+ CD31−. (B) FRC around blood vessels (pericytes) gp38− CD157+ CD31−. (C) FRC in the marginal zone (MRC) gp38+ CD31− CXCL13+. (D) Blood vessel endothelial cells (BEC) gp38− CD157+ CD31+. (E) Lymphatic endothelial cells (LEC) gp38+ CD157− CD31+ (E).
Figure 3Chemokine production by FRC and endothelial subsets according to Malhotra et al. [28]. (a) FRCs are able to secrete CCL19, CCL21 the ligand of CCR7, CXCL12 ligand of CXCR4, and CXCL13 ligand of CXCR5. (b) BECs express CXCL12 the ligand of CXCR4. (c) LECs express CCL20 the ligand of CCR6.
Figure 4Il-7 in combination with CCL19 and CCL21 leads naive T cell to survival probably by acting in the imbalance of pro- and antiapoptotic proteins.
Figure 5While the expression of AIRE by stromal cells is still a controversy, Turley et al. [14] suggest a role for DF1 and DF1-VAR1 isoforms of DEAF1, on PTAs expression by FRC and the peripheral homeostasis.